After the new Saudi law which requires that a part of the manufacturing process is executed in the country as a re condition to be allowed to sell products in KSA, some multinational companies have launched projects to have a local production capability.
Pfizer Saudi required a new solid dose manufacturing facility for the production and packaging of pharmaceuticals. Planned to produce 18 million packs per year, the facility will produce a broad range of Pfizer’s medicines currently supplied to the Kingdom of Saudi Arabia.
This grassroots secondary facility will produce solid dosage forms, and includes production functions (manufacturing, primary and secondary packaging) and support areas (QC labs, warehouse, services, staff support areas). The total developed surface area of the new plant is in the range of 11,000 sqm.
We have been involved in providing services for Pfizer’s pharmaceutical facility in Saudi Arabia since its inception in 2010.
We are currently involved in driving the qualification phase ie. the final set of tests necessary to provide “documented evidence” that the facility complies with the project user requirements. Qualification is planned to be completed in June 2016. Afterwards, the trial batches will be launched and Pfizer will seek for the authorisation to produce from the local authorities.
|Location:||King Abdullah Economic City (KAEC), Saudi Arabia|
|Client:||Pfizer Saudi Ltd|
|Scope:||Contract services (in cooperation with a local partner), site master plan, conceptual and basic design, detailed engineering, support for subcontracting, technical support, commissioning and qualification management|
|Date:||2010 – ongoing|